DENVER, July 14 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, announced today that it will host an investor day to
review its clinical development and research programs on Thursday, July 15th
at 8:00 a.m. Eastern.
Presenters include:
J. William Freytag, Ph.D., President & CEO
Michael Gerber, M.D., Senior Vice President, Clinical Development &
Regulatory Affairs
Richard Gorczynski, Ph.D., Senior Vice President, Research & Development
Henry Black, M.D., Rush University Medical Center
Lewis Rubin, M.D., University of California, San Diego
Eric Eichhorn, M.D., Cardiopulmonary Research Science and Technology
Institute
Eric Olson, Ph.D., University of Texas Southwestern Medical Center
The presenters who are not Myogen employees are not representatives of the
Company and any opinions they may express are their own and not official
statements of Myogen.
Interested investors can access a live audio webcast of the presentation
at http://investor.myogen.com. An on-demand replay of the webcast will be
archived and available at the same site.
Myogen currently markets one product in Europe for the treatment of acute
decompensated heart failure and has three product candidates in late-stage
clinical development: enoximone capsules for the treatment of chronic heart
failure, ambrisentan for the treatment of pulmonary arterial hypertension and
darusentan for the treatment of resistant hypertension. The Company, in
collaboration with Novartis, also conducts a target and drug discovery
research program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentations contain forward-
looking statements that involve significant risks and uncertainties, including
those discussed in this release, those to be discussed in the presentation and
others that can be found in the "Risk Factors" section of Myogen's Form 10-K
for the year ended December 31, 2003 and in Myogen's periodic reports on
Form 10-Q and Form 8-K. Myogen does not undertake any obligation to update
any forward-looking statements contained in this document or the anticipated
presentation as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the forward-looking
statements contained in this press release or the presentation. No forward-
looking statement can be guaranteed and actual events and results may differ
materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://investor.myogen.com
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
